Affiliated with a Castle Connolly Top Hospital
Who is Dr. So, Surgeon in Stanford, CA?
Dr. Samuel So, MD is a Surgeon, who primarily practices in Stanford, CA. He is board certified. Dr. So graduated from University of Hong Kong, China and completed his residency at University of Minnesota. Dr. So is fluent in English and Chinese, and is currently seeing new patients. Dr. So’s practice accepts Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. So’s office.
What are Areas of Expertise for Dr. So?
Dr. Samuel So, MD is a highly-rated, board-certified Surgeon known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. So empowers patients to confidently navigate their health journey, specializing in Liver Tumors, Surgical Oncology, and comprehensive wellness support. Serving the Stanford, CA community, Dr. So is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. So go to medical school and complete their residency?
Fellowship: Univ. of Minnesota, Mpls., MN, Multi-organ Transplantation
Residency: University of Minnesota
Medical School: University of Hong Kong, China
Is Dr. So board certified as a Surgeon?
Yes, Dr. Samuel So, MD is board certified by the American Board of Radiologic Physics , American Board of Radiology
What languages does Dr. So speak?
Dr. So and their clinical team can communicate with patients in the following languages:
Chinese
English
What conditions does a Surgeon like Dr. So typically treat?
As a Surgeon, Dr. So diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. So. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Chronic Hepatitis B
- Hepatitis B
- Long-term Hepatitis B
- Persistent Hepatitis B
- Hep B
ICD-10 Codes:
- B181: Chronic viral hepatitis B without delta-agent
Also known as:
- Liver Cancer
- Childhood Liver Cancer
- Hepatic Cancer
- Hepatocellular Carcinoma
ICD-10 Codes:
- C220: Liver cell carcinoma
Also known as:
- History of liver cancer
- Liver Cancer
- Past liver cancer
- Hepatic cancer survivor
- Previous liver malignancy
ICD-10 Codes:
- Z8505: Personal history of malignant neoplasm of liver
What procedures does a Surgeon like Dr. So typically perform?
As a Surgeon, procedures performed by Dr. Samuel So may include:
- Abdominal Wall Reconstruction
- Amputation
- Appendicitis / Appendectomy
- Brain Aneurysm Treatment
- Brain Surgery
- Brain Tumor Evaluation
- Central Line Placement
- Cerebral Shunt
Please contact Dr. So's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. So accept my insurance?
Dr. So accepts most major insurance plans. Important: Please call our office at before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. So accept in Stanford, CA?
Dr. So in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicare
UnitedHealth Group
Valley Health Plan
View All Insurances
Where is Dr. So's office located?
Recognitions
Publications
Suppressing N-Myc downstream regulated gene 1 reactivates senescence sigling
, 2014
Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives
, 2014
Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor
, 2013
Education and counseling of pregnt patients with chronic hepatitis B
, 2013
Assessment and comparison of magnetic noparticles as MRI contrast agents in a rodent model of human
, 2012
Low Levels of Knowledge
, 2012
A model program for hepatitis B vaccition and education of schoolchildren in rural Chi
, 2012
The CD47-sigl regulatory protein alpha
, 2012
San Francisco Hep B Free: A Grassroots Community Coalition to Prevent Hepatitis B and Liver Cancer
, 2011
Soluble Frizzled-7 receptor inhibits Wnt sigling
, 2011
Disparities in Liver Cancer Incidence by tivity, Acculturation
, 2010
Small molecule antagonists of Tcf4
, 2010
Achieving health equity to elimite racial, ethnic
, 2010
Hepatitis B and liver cancer knowledge and practices among healthcare and public health professiols
, 2010
Cost-Effectiveness of tionwide Hepatitis B Catch-up Vaccition Among Children and Adolescents in Chi
, 2010
Blockade of Wnt-1 sigling leads to anti-tumor effects in hepatocellular carcinoma cells
, 2009
The Jade Ribbon Campaign
, 2009
Frequent Ictivation of Axon Guidance Molecule RGMA in Human Colon Cancer Through Genetic
, 2009
Stopping a Silent Killer in the Underserved Asian and Pacific Islander Community
, 2009
3 For Life: A Model Pilot Program to Prevent Hepatitis B Virus Infection and Liver Cancer in Asian
, 2009
Elimiting the Threat of Chronic Hepatitis B in the Asian and Pacific Islander Community
, 2009
Small interfering R targeting CDC25B inhibits liver tumor growth in vitro and in vivo
, 2008
Phase H study of imatinib in unresectable hepatocellular carcinoma
, 2008
Attitudes toward Hepatitis B
, 2008
Building partnerships with Traditiol Chinese Medicine Practitioners to incre
, 2007
Re: Ten largest racial and ethnic health disparities in the United States based on healthy people
, 2007
Cost-effectiveness of screening and vacciting Asian and pacific islander adults for hepatitis B
, 2007
Why we should routinely screen Asian American adults for hepatitis B
, 2007
Hepatitis B and liver cancer knowledge and preventive practices among Asian Americans
, 2007
Comprehensive alysis of 19q12 amplicon in human gastric cancers
, 2006
Sprouty 2, an inhibitor of mitogen-activated protein kise sigling
, 2006
Topological and functiol discovery in a gene coexpression meta-network of gastric cancer
, 2006
Liver tumor gross margin identification
, 2005
An integrated data alysis approach to characterize genes highly expressed
, 2005
Phospholipase A2 group IIA expression
, 2002
Comprehensive alysis of the gene expression profiles in human gastric cancer cell lines
, 2002
Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion.
, 2002
Identify metastasis-associated genes in hepatocellular carcinoma through clolity delineation for
, 2002
Impact of multidetector CT hepatic arteriography on the planning of chemoembolization treatment
, 2001
Genomic alysis of human hepatocellular carcinoma gene expression using cD microarrays.
, 1999
Minimal criteria for placement of adults on the liver transplant waiting list
, 1998
Posttransplant lymphoproliferative disorders
, 1998
Minimal criteria for placement of adults on the liver transplant waiting list
, 1997
Transjugular intrahepatic portosystemic shunt placement in a child complicated by perforated Roux
, 1997
Superior outcomes in pediatric rel transplantation
, 1997
Emergency transjugular intrahepatic portosystemic shunt (TIPS) in an infant: A case report
, 1997
Continuous venovenous hemofiltration with dialysis in combition with total hepatectomy
, 1996
FULMINT HEPATIC-FAILURE FOLLOWING VARICELLA
, 1995
ACUTE LIVER ALLOGRAFT-REJECTION IN THE RAT - AN ALYSIS OF THE IMMUNE RESPONSE
, 1995
EX-VIVO TECHNIQUE FOR RIGHT LOBECTOMY IN PEDIATRIC HEPATIC TRANSPLANTATION
, 1994
RESPIRATORY-DISTRESS FROM BENIGN LIVER
, 1994
Suppressing N-Myc downstream regulated gene 1 reactivates senescence signaling
, 2014
Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives
, 2014
Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor
, 2013
Education and counseling of pregnant patients with chronic hepatitis B
, 2013
Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of
, 2012
Low Levels of Knowledge
, 2012
A model program for hepatitis B vaccination and education of schoolchildren in rural China
, 2012
The CD47-signal regulatory protein alpha
, 2012
Suppression of Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up
, 2011
San Francisco Hep B Free: A Grassroots Community Coalition to Prevent Hepatitis B and Liver Cancer
, 2011
In vivo MRSI of hyperpolarized [1-C-13]pyruvate metabolism in rat hepatocellular carcinoma
, 2011
Doing Good with Good OR: Supporting Cost-Effective Hepatitis B Interventions
, 2011
Comparative Profiling of Primary Colorectal Carcinomas
, 2011
Soluble Frizzled-7 receptor inhibits Wnt signaling
, 2011
Disparities in Liver Cancer Incidence by Nativity, Acculturation
, 2010
Small molecule antagonists of Tcf4
, 2010
Achieving health equity to eliminate racial, ethnic
, 2010
Hepatitis B and liver cancer knowledge and practices among healthcare and public health
, 2010
Cost-Effectiveness of Nationwide Hepatitis B Catch-up Vaccination Among Children
, 2010
Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma
, 2009
Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells
, 2009
The Jade Ribbon Campaign
, 2009
Frequent Inactivation of Axon Guidance Molecule RGMA in Human Colon Cancer Through Genetic
, 2009
Stopping a Silent Killer in the Underserved Asian and Pacific Islander Community
, 2009
3 For Life: A Model Pilot Program to Prevent Hepatitis B Virus Infection and Liver Cancer in Asian
, 2009
Eliminating the Threat of Chronic Hepatitis B in the Asian and Pacific Islander Community
, 2009
N-Myc down-regulated gene 1 mediates proliferation, invasion
, 2008
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
, 2008
Phase H study of imatinib in unresectable hepatocellular carcinoma
, 2008
Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma.
, 2008
Attitudes toward Hepatitis B
, 2008
Building partnerships with Traditional Chinese Medicine Practitioners to incre
, 2007
Re: Ten largest racial and ethnic health disparities in the United States based on healthy people
, 2007
Cost-effectiveness of screening and vaccinating Asian and pacific islander adults for hepatitis B
, 2007
Why we should routinely screen Asian American adults for hepatitis B
, 2007
The burden of liver cancer in Asians and Pacific Islanders in the greater San Francisco Bay Area
, 2007
Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma
, 2007
Hepatitis B and liver cancer knowledge and preventive practices among Asian Americans
, 2007
Comprehensive analysis of 19q12 amplicon in human gastric cancers
, 2006
Gallium maltolate is a promising chemotherapeutic agent
, 2006
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling
, 2006
Topological and functional discovery in a gene coexpression meta-network of gastric cancer
, 2006
Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations
, 2005
Liver tumor gross margin identification
, 2005
An integrated data analysis approach to characterize genes highly expressed
, 2005
Mutations of PIK3CA in gastric adenocarcinoma
, 2005
Transcript AA454543 is a novel prognostic marker
, 2005
Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma
, 2005
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
, 2005
Granulin-epithelin precursor overexpression promotes growth
, 2004
High prevalence of chronic hepatitis B
, 2004
Novel endothelial cell markers in hepatocellular carcinoma
, 2004
Expression profiling identifies chemokine
, 2004
One hundred percent patient and kidney allograft survival with simultaneous liver and kidney
, 2003
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma
, 2003
Variation in gene expression patterns in human gastric cancers
, 2003
Phospholipase A2 group IIA expression
, 2002
Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines
, 2002
Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion.
, 2002
Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for
, 2002
Gene expression patterns in human liver cancers
, 2002
Epstein-Barr virus infection is associated with endothelial bcl
, 2002
Impact of multidetector CT hepatic arteriography on the planning of chemoembolization treatment
, 2001
Studies of Pediatric Liver Transplantation (SPLIT): Year 2000 outcomes
, 2001
Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis
, 2001
CMV and EBV-PTLD after liver transplantation
, 2001
A 100% 2-year graft survival can be attained in high
, 2000
Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization.
, 2000
Intravenous ribavirin therapy for adenovirus pneumonia
, 2000
Significance of detecting Epstein-Barr
, 2000
CD81 gene expression is lost in hepatocellular carcinoma.
, 1999
Resection versus transplantation for hepatocellular carcinoma
, 1999
Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation
, 1999
Major hepatic resection without blood transfusion: Experience with total vascular exclusion
, 1999
Genomic analysis of human hepatocellular carcinoma gene expression using cDNA microarrays.
, 1999
Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
, 1999
Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation
, 1999
Increased dosage requirement
, 1998
Minimal criteria for placement of adults on the liver transplant waiting list
, 1998
Posttransplant lymphoproliferative disorders
, 1998
Combined viral prophylactic and immunosuppressive strategy in liver transplantation
, 1998
Liver transplantation in the first three months of life
, 1998
Allograft rejection after liver transplantation for autoimmune liver diseases
, 1998
Indications for pediatric liver transplantation.
, 1998
Current status of living-related liver transplantation.
, 1998
Experience with the piggyback technique without caval occlusion
, 1998
Liver transplantation at Stanford University Medical Center.
, 1998
Minimal criteria for placement of adults on the liver transplant waiting list
, 1997
Transjugular intrahepatic portosystemic shunt placement in a child complicated by perforated Roux
, 1997
Superior outcomes in pediatric renal transplantation
, 1997
Factors affecting survival after orthotopic liver transplantation in infants
, 1997
Potential effect of cyclosporin A in formation of cholesterol gallstones in pediatric liver
, 1997
Orthotopic liver transplantation from non-heart-beating donor rats: Effect of flushing with cold
, 1997
Emergency transjugular intrahepatic portosystemic shunt (TIPS) in an infant: A case report
, 1997
Liver transplantation in Asian patients with chronic hepatitis B
, 1997
Primary liver transplantation without transfusion of red blood cells
, 1996
Orthotopic liver transplantation for hepatocellular carcinoma - Factors affecting long
, 1996
Continuous venovenous hemofiltration with dialysis in combination with total hepatectomy
, 1996
Cyclosporine and tacrolimus both suppress activation of kupffer cells in vitro
, 1996
Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation
, 1996
Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients
, 1996
Expression of cytokines and immune mediators during chronic liver allograft rejection
, 1995
THE USE OF NON-HEART-BEATING CADAVER DONORS IN EXPERIMENTAL LIVER-TRANSPLANTATION
, 1995
FULMINANT HEPATIC-FAILURE FOLLOWING VARICELLA
, 1995
A REASSESSMENT OF ABO INCOMPATIBILITY IN PEDIATRIC LIVER-TRANSPLANTATION
, 1995
LIVER-TRANSPLANTATION IN A CHILD WITH SICKLE-CELL-ANEMIA
, 1995
EFFECTS OF PENTOXIFYLLINE PRETREATMENT ON KUPFFER CELLS IN RAT-LIVER TRANSPLANTATION
, 1995
ISOLATED ALKALINE PHOSPHATEMIA FOLLOWING PEDIATRIC LIVER-TRANSPLANTATION IN THE FK506 ERA
, 1995
DIFFERENTIAL PATTERNS OF CIRCULATING INTERCELLULAR-ADHESION MOLECULE-1
, 1995
FK506 (TACROLIMUS) COMPARED WITH CYCLOSPORINE FOR PRIMARY IMMUNOSUPPRESSION AFTER PEDIATRIC LIVER
, 1995
AN INCREASED INCIDENCE OF EPSTEIN-BARR
, 1995
IMPACT OF REDUCED-SIZE LIVER
, 1995
CHARACTERIZATION OF CYTOKINE EXPRESSION IN AN ANIMAL-MODEL OF ACUTE LIVER ALLOGRAFT-REJECTION
, 1995
FK-506 RESCUE THERAPY FOR HEPATIC ALLOGRAFT-REJECTION - EXPERIENCE WITH AN AGGRESSIVE APPROACH
, 1995
LONG-TERM NONRESPONSIVENESS TO A LIVER ALLOGRAFT MAY BE CYTOKINE-MEDIATED
, 1995
DISTINCT PATTERNS OF TH2 CYTOKINE PRODUCTION DURING IMMUNE ACTIVATION IN PEDIATRIC LIVER ALLOGRAFT
, 1995
MOLECULAR MARKERS OF EPSTEIN-BARR-VIRUS INFECTION IN THE CIRCULATION OF TRANSPLANT RECIPIENTS
, 1995
CIRCULATING INTERCELLULAR-ADHESION MOLECULE
, 1995
ACUTE LIVER ALLOGRAFT-REJECTION IN THE RAT - AN ANALYSIS OF THE IMMUNE RESPONSE
, 1995
EX-VIVO TECHNIQUE FOR RIGHT LOBECTOMY IN PEDIATRIC HEPATIC TRANSPLANTATION
, 1994
NEUROLOGICAL COMPLICATIONS OF LIVER-TRANSPLANTATION IN ADULT VERSUS PEDIATRIC-PATIENTS
, 1994
RESPIRATORY-DISTRESS FROM BENIGN LIVER
, 1994
FK506 CONVERSION THERAPY IN PEDIATRIC LIVER-TRANSPLANTATION
, 1994
PREVENTION OF REJECTION AND GRAFT LOSS WITH AN AGGRESSIVE QUADRUPLE IMMUNOSUPPRESSIVE THERAPY
, 1994
INDUCTION IMMUNOSUPPRESSION WITH ANTILYMPHOCYTE GLOBULIN OR OKT3 IN CADAVER KIDNEY-TRANSPLANTATION
What is Dr. So's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. So's National Provider Identifier (NPI) number is 1982730065.
What common questions do patients ask about Dr. So?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. So
What is Dr. Samuel So's specialty?
Dr. So is a Surgeon near Stanford, CA.
What does a Surgeon do?
General surgeons are experts in diagnosing and managing surgical conditions which includes preoperative, operative, and postoperative care, as well as addressing complications. Their expertise include the areas such as the alimentary tract, breast, abdomen, skin and soft tissue, endocrine system, head and neck, pediatric surgery, surgical critical care, surgical oncology, trauma, burns, and vascular surgery. General surgeons increasingly utilize minimally invasive and endoscopic techniques to provide proper care. In addition to this, many general surgeons have expertise in transplantation, plastic, and cardiothoracic surgery.
Is this Dr. Samuel So affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. So is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Surgeon?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Surgeon. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Samuel So accepting new patients in Stanford, CA?
Yes, Dr. Samuel So is accepting new patients at this time.
Does Dr. Samuel So offer online booking?
Please contact Dr. So's office for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Samuel So?
Please contact Dr. So's office for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Samuel So have?
Dr. Samuel So is certified by the American Board of Radiologic Physics and American Board of Radiology.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>
Connect with DR. So
Clinic B
300 Pasteur Dr
Stanford, CA 94305